Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design
暂无分享,去创建一个
R. Becker | T. Povsic | S. Zelenkofske | J. Alexander | R. Harrington | M. Chan | C. Rusconi | W. Wargin | M. G. Cohen